Mobile immunotherapy with chimeric antigen receptor (CAR)-T cells (CARTs) represents a breakthrough within the therapy of hematologic malignancies. CARTs are genetically engineered hybrid receptors that
Immunology and Cancer Biology University of California
Apoptosis, flow, mitochrondria, FITC, cytoplasmic membrane, oncoprotein